First gene therapy product
could enter market in Q1 2018

Jafral, manufacturing biological macromolecules

The U.S. FDA has approved an application for a gene therapy for blindness. The proposed gene therapy is a potential one-time treatment — verging on a cure — for a rare genetic form of blindness caused by a gene mutation. If approved, the first gene therapy could hit the market as early as January.